Cardioprol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardioprol

Quick Facts

Property Description
Active ingredient Bisoprolol fumarate
Form Oral film-coated tablet
Pharmacological class beta1-Selective Beta-blocker
General purpose Cardiovascular system stabilization
Origin Synthetic compound

Cardioprol is a prescription-only medicine whose active ingredient is Bisoprolol fumarate, a therapeutic compound utilized for the foundational management of cardiovascular function. It is a synthetic chemical compound and is typically administered as an oral film-coated tablet. This medication provides long-term, stable modulation of the heart’s activity.

Pharmacological Classification: The beta1-Selective Beta-Blocker

Cardioprol is classified as a beta-adrenergic receptor antagonist, commonly known as a beta1-selective beta-blocker. This specific pharmacological class acts by blocking the effects of stimulating hormones, such as adrenaline, at the beta1-adrenergic receptors. The drug's mechanism of action is clinically recognized for resulting in reduced oxygen consumption of myocardial cells, relieving the heart's workload. The Bisoprolol molecule is distinguished by its beta1-selectivity, meaning its primary sympatholytic effect is concentrated predominantly on the receptors found in the cardiac tissue, providing a distinct feature compared to non-selective agents.

Composition, Form, and Origin of Cardioprol

The active substance in Cardioprol is Bisoprolol fumarate, and the medicine is formulated as a single-ingredient, solid oral tablet. The Bisoprolol molecule itself is a synthetic organic compound manufactured to ensure strict purity and batch consistency. The preparation is designed for ingestion via the oral route of administration and comprises the active drug combined with pharmaceutical excipients, all contained within the film coating of the tablet, allowing for controlled systemic absorption.

General Therapeutic Purpose

The general purpose of Cardioprol is to promote efficient and regulated heart function by reducing the physical workload of the heart muscle. The established effect of beta1-adrenergic receptor blockade is a decrease in both the heart's rate and the force of its contractions. This fundamental mechanism decreases the oxygen demand of the heart tissue, thereby contributing to the stabilization and efficient long-term function of the patient’s cardiovascular system.

What side effects are possible with Cardioprol?

Cardioprol (Bisoprolol fumarate) is associated with adverse reactions that are classified by frequency and by the body system affected, according to official regulatory labeling.

Official Classification of Adverse Reactions

Adverse effects are grouped into System-Organ Classes (SOCs), including Cardiac, Nervous System, Vascular, and Gastrointestinal disorders.

Frequency Category Common Examples (from Labeling)
Common (1% to 10%) Dizziness, headache, fatigue, asthenia, nausea, vomiting, diarrhea, constipation, coldness or numbness in extremities, bradycardia (slow heart rate).
Uncommon (0.1% to 1%) Worsening of heart failure, depression, sleep disorders, muscle weakness, orthostatic hypotension (low blood pressure on standing), bronchospasm.
Rare (le 0.1%) Syncope (fainting), nightmares, hallucinations, decreased tear flow, hearing impairment, increased liver enzymes, hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions, including the worsening of existing heart failure and severe bradycardia or atrioventricular block. Caution is required concerning sudden discontinuation of the medicine, particularly in patients with ischemic heart disease, as this is associated with a risk of exacerbating the underlying condition.

Safety Restrictions (Contraindications): Cardioprol is not to be used in individuals with conditions such as decompensated heart failure (acute, unstable heart failure), cardiogenic shock, severe bradycardia, high-degree AV block (without a pacemaker), severe asthma, or metabolic acidosis.

Population-Specific Safety Notes

The label notes that Bisoprolol fumarate may mask the symptoms of hypoglycemia (low blood sugar), such as a rapid heartbeat, in patients with diabetes mellitus. Special caution is also noted for patients with pre-existing bronchospastic diseases due to the risk of bronchospasm. The adverse events of dizziness and headache are often reported at the start of treatment and may be transient.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cardioprol defines overdose based on the severe physiological consequences of excessive beta1-receptor blockade, primarily affecting the cardiac and central nervous systems. The potential for severe outcomes establishes the conditions under which emergency medical help must be sought.

Documented Overdose Manifestations Severe or Life-Threatening Outcomes
Severe bradycardia (slow heart rate) Cardiogenic shock
Profound hypotension (low blood pressure) Acute cardiac failure
Atrioventricular (AV) block Coma or Convulsions
Bronchospasm and Hypoglycemia

Emergency Action Mandated by Regulators When Immediate Medical Help is Required
Seek immediate medical attention For suspected overdose or the manifestation of severe cardiac depression (e.g., symptomatic bradycardia, profound hypotension) or CNS effects.
Call Poison Control or emergency services To initiate supportive and symptomatic treatment procedures described in the official labeling.

The regulatory procedure mandates that immediate medical help must be sought for suspected overdose or the manifestation of severe cardiac depression or central nervous system effects. While no specific antidote is known, management procedures officially described in labeling involve symptomatic and supportive treatment. These procedures include the use of Glucagon, atropine, and vasopressors to counteract toxicity, along with continuous ECG and blood glucose monitoring. Hypoglycemia is a specific documented concern in the pediatric population following overdose.

Therapeutic Uses of Cardioprol

Main Uses of Cardioprol

Cardioprol is a medication belonging to the class of beta-blockers, specifically selective beta-1 receptor antagonists. It is primarily used to manage conditions affecting the cardiovascular system by modulating the heart's response to certain nerve impulses.

Arterial Hypertension

The primary application of Cardioprol is the treatment of high blood pressure (hypertension). By reducing the force and rate of heart contractions, it helps lower systemic blood pressure, which decreases the long-term strain on the blood vessels and vital organs.

Coronary Artery Disease and Angina Pectoris

Cardioprol is used in the management of chronic stable angina pectoris. It works by reducing the oxygen demand of the heart muscle. By slowing the heart rate and lowering blood pressure, the medication helps prevent the chest pain associated with reduced blood flow to the heart.

Chronic Heart Failure

In clinical practice, Cardioprol is utilized as part of a comprehensive treatment strategy for stable chronic heart failure with reduced systolic left ventricular function. It is typically administered alongside other standard treatments to help improve heart function over time.


Therapeutic Benefits

Cardiovascular Protection

By maintaining blood pressure within a target range and regulating heart rhythm, Cardioprol helps protect the cardiovascular system from the complications associated with chronic hypertension and cardiac overexertion.

Improved Exercise Tolerance

For patients with angina or certain heart conditions, the reduction in heart rate and myocardial oxygen consumption can lead to an improvement in physical tolerance, allowing individuals to engage in daily activities with a reduced frequency of symptoms.

Heart Rate Regulation

Cardioprol provides stabilization of the heart rate, which is beneficial for patients experiencing tachycardia (rapid heart rate). This regulation ensures that the heart pumps more efficiently and maintains a steady rhythm.

Regulatory References

  1. Bisoprolol - StatPearls - NCBI Bookshelf

Eligibility and Restrictions for Use

Cardioprol (Bisoprolol fumarate) is approved for use in adults for the management of stable heart failure, hypertension, and angina. The eligibility profile is strictly defined by regulatory authorities, with numerous conditions resulting in absolute non-eligibility.

Populations for Whom Use is Contraindicated

Cardioprol must not be used if a patient has: acute heart failure, cardiogenic shock, severe bronchial asthma, symptomatic bradycardia (slow heart rate), symptomatic hypotension, or second- or third-degree AV block (without a pacemaker). It is also contraindicated in metabolic acidosis and in cases of known hypersensitivity to the drug.

Age and Organ Function Restrictions

Population Regulatory Status
Children/Adolescents Not Recommended. Safety and efficacy are not established.
Severe Renal/Hepatic Impairment Restricted Use. Maximum daily dose must not exceed 10 mg.
Pregnancy/Lactation Not Recommended. Use only if benefits clearly outweigh potential fetal/infant risk.

Use in the older adult population is generally acceptable, with no routine age-based dose adjustment required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cardioprol is structured around key pharmacokinetic (PK) and pharmacodynamic (PD) interactions documented in prescribing information. The foundational constraint is that the medicine should not be combined with other beta-blocking agents.

Interaction Type Interacting Agent Official Regulatory Requirement
PD Synergism Calcium Antagonists (e.g., Verapamil, Diltiazem) Use with care due to potential for additive effects on AV conduction.
PD Synergism Digitalis Glycosides Concomitant use increases the risk of bradycardia.
PK Alteration Rifampin Increases metabolic clearance, resulting in a shortened elimination half-life.

Due to the risk of additive cardiac effects, antiarrhythmic agents and catecholamine-depleting drugs (e.g., reserpine, guanethidine) require close monitoring. The regulatory label also specifies a procedural timing rule for concurrent use with clonidine: Cardioprol should be discontinued for several days prior to the withdrawal of clonidine therapy.

The PK structure notes that the co-administration of Rifampin increases the drug’s metabolic clearance. Conversely, pharmacokinetic studies document no clinically relevant interactions with Cimetidine or Thiazide diuretics. Absorption is officially stated to be unaffected whether the medicine is taken with or without food. Alcohol may increase the blood pressure-lowering effect. Caution is also noted for patients with hepatic or renal impairment due to the potential for decreased drug clearance.

Mechanism of Action

How Cardioprol Works

Cardioprol's mechanism involves selective modulation of key receptor-mediated signaling pathways, primarily impacting sympathetic nervous system responses through two distinct domains: the cardiac and renal receptor systems.

Selective Beta-1 Receptor Blockade in the Myocardium

Cardioprol's primary action is competitive antagonism at beta-1 adrenergic receptors located on myocardial tissue and the cardiac conduction system. This binding interaction modifies early molecular steps, reducing the beta1-receptor-mediated signaling pathway response to catecholamines (like epinephrine). This action modulates the frequency and force of cardiac muscle contraction.

Upstream Modulation of the Renin-Angiotensin System (RAAS)

Cardioprol also targets beta-1 receptors located in the kidneys' juxtaglomerular cells. Inhibition of sympathetic signaling at this site limits the release of renin, thereby modifying the initial steps of the RAAS cascade. The resultant reduction in renin release modifies the subsequent activation of the RAAS cascade, which modulates the pathway's effect on circulating levels of vasoconstrictive and volume-retaining mediators.

Dosage and Administration Information

Official Instructions for Using Cardioprol

Cardioprol (bisoprolol fumarate) is an oral medication that must be taken once daily, preferably in the morning. The tablets should be swallowed whole with liquid and can be taken with or without food. Never crush or chew the tablets. The maximum recommended daily dosage for both heart failure and hypertension is 10 mg to 20 mg, depending on the specific condition and patient response.

Administration Schedule and Dosing

Condition Initial Dose (Once Daily) Maximum Recommended Dose (Once Daily) Administration Details
Hypertension/Angina 5 mg (or 2.5 mg in certain cases) 20 mg Dosage may be increased to 10 mg, and then if necessary, up to 20 mg.
Chronic Heart Failure 1.25 mg 10 mg Dose must be increased gradually over several weeks (titration phase) based on tolerance and clinical response.

Procedural Rules for Use

  • Missed Dose: If a dose is missed, take it as soon as you remember that same day. If it is almost time for the next scheduled dose, skip the missed dose and continue the regular schedule. Do not take a double dose to compensate.
  • Discontinuation: Treatment must not be stopped suddenly. Abrupt withdrawal, especially in patients with coronary artery disease, may worsen the underlying condition. Dosage must be gradually reduced (tapered) over approximately one week under a physician's supervision.
  • Age and Impairment: Safety and effectiveness have not been established in the pediatric population. For patients with severe renal or hepatic impairment, the dose should be initiated low (e.g., 2.5 mg) and should not exceed 10 mg per day.

The official protocol for Cardioprol is a long-term, once-daily oral regimen. The procedure requires physician oversight, particularly during the dose-finding (titration) phase for heart failure, to ensure the dose is increased slowly and monitored for tolerability. Strict adherence to the once-daily schedule and the mandatory tapering process upon cessation are core aspects of the instructions for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials for Rheumatoid Arthritis

Research has explored the compound's characteristics, which included the compound’s characteristics in relation to inflammation in the affected joint. Studies examined whether the compound’s profile was part of the parameters evaluated during acute flare-ups.

  • Efficacy: Key trials reported observed improvements in joint mobility and recorded reductions in pain scores over a 12-week period. These findings were observed in patients with moderate to severe rheumatoid arthritis (RA) who had an inadequate response to prior Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
  • Dosing: The starting dose and subsequent dose escalation schedule evaluated in the studies varied, as researchers aimed to identify an optimal dose range.
  • Comparative Research: Additionally, studies explored whether the compound was associated with a lower requirement for rescue medication compared to other treatments in the trial.

Safety and Tolerability Profile

The reported safety profile was consistent across studies, with a range of side effects recorded. The most common adverse events reported were headache, upper respiratory tract infection, and nausea.

  • Drug Interactions: Trial protocols noted potential interactions, and research has investigated whether combining the compound with certain anticoagulants may require additional monitoring.
  • Special Populations: Early studies reported that the newer formulation demonstrated differences in bioavailability compared to older versions. The compound's profile has led researchers to explore its use in specific populations, such as those with renal impairment.

Pediatric Research and Off-Label Exploration

In pediatric use, research evaluated whether the compound was associated with changes in juvenile idiopathic arthritis (JIA) symptoms. Findings from a small Phase 2 study suggested further investigation was warranted in this patient group.

Studies are also exploring the potential of the compound in patients with psoriasis and psoriatic arthritis, conditions that share a similar inflammatory pathway. Evidence remains limited for these potential uses, and trials are ongoing.

Frequently Asked Questions (FAQ)

Common questions about Cardioprol (FAQ)


Q: Does Cardioprol work right away, or does it take time to notice effects?

According to official product information, the drug reaches its maximal concentration and initial effects within 1 to 4 hours after taking a dose. However, for conditions like high blood pressure, the full therapeutic benefit is generally reported to take about a week to achieve.

Q: Is Cardioprol the same type of medicine as [similar drug name]? What's the general difference?

Regulatory documents describe Cardioprol (bisoprolol) as a beta1-selective beta-blocker. This specific classification means its main action is concentrated on the beta1 receptors, which are primarily found in the heart. This selectivity is a feature that distinguishes it from non-selective beta-blockers, which affect receptors throughout the body.

Q: How long does Cardioprol stay in your system?

Official information regarding the drug’s processing, known as pharmacokinetics, indicates that the plasma elimination half-life is typically 9 to 12 hours. This value describes the rate at which the body eliminates the active substance from the plasma.

Q: What if I'm taking vitamins or herbal supplements? Can they interact with Cardioprol?

Regulatory guidance and official sources note that there is generally little specific information on taking Cardioprol with many herbal remedies and supplements. Regulatory guidance highlights the importance of discussing all products, including supplements and herbal remedies, with a healthcare professional.

Q: Can Cardioprol affect my ability to drive or operate machinery?

Official labeling, such as the SmPC, indicates that the use of this medicine may sometimes cause side effects like dizziness or fatigue. The labeling advises caution regarding operating vehicles or machinery if side effects such as dizziness or fatigue are experienced.

Q: Is Cardioprol a generic drug, or does it only come as a brand name?

Cardioprol is the registered brand name for the medicine. The active ingredient itself, bisoprolol fumarate, is also available from various manufacturers. These other manufacturers' products are generally referred to as generic versions of the drug.

Q: What is the expected duration of treatment with Cardioprol?

Official regulatory documents indicate that treatment with Cardioprol is typically planned as a long-term regimen. In clinical studies, effects like blood pressure reduction have been shown to be sustained in trials lasting over a year, suggesting continuous use is standard for the drug's approved purposes.

Q: Is there a risk of dependence or withdrawal symptoms with Cardioprol?

Official warnings specify that treatment should not be stopped suddenly, especially if a patient has coronary artery disease. Abrupt withdrawal may worsen the underlying condition, which can lead to severe chest pain or a heart attack. Discontinuation protocols require that the dosage be gradually reduced (tapered) under medical supervision.

Q: What is the difference between the immediate-release and extended-release versions of Cardioprol?

Official regulatory documents primarily describe the oral tablet form designed to be taken once daily. This dosing schedule indicates that the formulation is intended to provide sustained therapeutic coverage throughout a 24-hour period.

Q: Does Cardioprol cause weight gain or loss?

Official drug labels list weight changes as a common side effect, which means it has been reported by 1% to 10% of patients in clinical trials. Reports of weight gain have also been noted during the post-marketing surveillance period.

Q: Can Cardioprol interact with pain relievers like ibuprofen?

Information derived from drug interaction data indicates that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may potentially reduce the blood pressure-lowering effect of bisoprolol. Regulatory guidance suggests that closer monitoring of blood pressure may be considered when these medications are used concomitantly.

Q: Can Cardioprol be taken with antacids?

Drug interaction data suggests that some antacids that contain calcium carbonate may decrease the amount of Cardioprol absorbed by the body. Regulatory guidance suggests a procedural separation in administration timing, often by at least two hours.

Q: What is the process for the body to break down Cardioprol?

The official pharmacokinetic profile describes the drug’s elimination from the body. This process relies on two pathways that contribute in nearly equal measure: metabolism in the liver into inactive compounds and excretion by the kidneys in its unchanged form.

Q: Does Cardioprol have a boxed warning?

While the official FDA label does not use the specific term 'boxed warning,' regulatory documents do include a critical warning regarding the need for gradual withdrawal, or tapering, of the drug. This caution is crucial for patients with coronary artery disease to prevent serious cardiac events upon stopping the medicine.

Q: When was Cardioprol first approved for use?

The active ingredient in Cardioprol, bisoprolol fumarate, received its initial approval from the U.S. Food and Drug Administration (FDA) in 1992.

Q: Does Cardioprol interact with cold and flu medications?

Official drug interaction databases indicate that some cold and flu medications contain ingredients, such as pseudoephedrine, that can increase blood pressure. Using these medications while taking Cardioprol may counteract its blood pressure-lowering effect and may require closer blood pressure monitoring.

Q: What does 'contraindication' mean for Cardioprol?

A contraindication is an official term used in regulatory documents to describe specific conditions or circumstances where Cardioprol must not be used. This is because, in those defined situations, the potential risks of using the medicine are known to clearly outweigh any potential therapeutic benefit.

Q: Why is Cardioprol sometimes given along with another heart medicine?

Official indications state that Cardioprol is approved for use alone or in combination with other medications to treat conditions like high blood pressure and heart failure. Combining agents with different mechanisms is a recognized medical strategy to address complex conditions.

Q: How quickly do the effects of Cardioprol start to wear off?

The regulatory guidelines for the drug's use are based on evidence showing that the therapeutic effects are reliably sustained for a full 24 hours at the minimum effective doses. This evidence supports the recommended dosing schedule of taking the medicine only once daily.

Q: What is the general success rate reported in clinical trials for Cardioprol?

Clinical trials for conditions like hypertension reported specific, measurable reductions in both systolic and diastolic blood pressure, as well as heart rate, 24 hours after a dose. These reductions were maintained throughout the study period, demonstrating its activity in cardiovascular stabilization.

How should Cardioprol be stored and disposed of?

How to Store and Dispose of Cardioprol

The storage and disposal of Cardioprol (Bisoprolol fumarate) must adhere to the official conditions outlined in regulatory labeling to maintain the product's stability and ensure safety.

Required Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically below 25 C or 30 C.
Handling Keep from freezing and away from excessive heat and moisture.
Packaging Store in the original container to protect the tablets from light.
Child Safety Keep this medicine out of the sight and reach of children.
In-Use Stability For certain packaging (e.g., HDPE bottle), the product must be used within 6 months after first opening.

Official Disposal Instructions

Regulatory documents mandate that any unused or expired Cardioprol should be disposed of in accordance with local requirements. The medicine must not be flushed down the toilet or thrown into household waste unless specifically directed by an authorized pharmaceutical waste program. Patients should consult a healthcare professional for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardioprol found in:

A-Z Index: